Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'Idelalisib Trial Stopped Because of 'Overwhelming Efficacy'

In chronic lymphocytic leukemia, idelalisib combined with bendamustine and rituximab improved progression-free and overall survival compared with the standard two-drug combination. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news